Policy | June 28, 2022
R&D key for the growth of nation: Dr. Mandaviya
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Subscribe To Our Newsletter & Stay Updated
